Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
Susan Bal(University of Alabama at Birmingham), Jesús G. Berdeja(Tennessee Oncology), Allison Kaeding(Bristol-Myers Squibb (United States)), Adriana Rossi(Icahn School of Medicine at Mount Sinai), LD Anderson(The University of Texas Southwestern Medical Center), Naomey Sarkis(Bristol-Myers Squibb (United States)), Michael R. Burgess(Bristol-Myers Squibb (United States)), Wei-Ming Kao(Bristol-Myers Squibb (United States)), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), Daniel Nathan Egan(Swedish Medical Center), Tom Martin(UCSF Helen Diller Family Comprehensive Cancer Center), Mehmet Kocoglu(University of Maryland, Baltimore), Omar Nadeem(Dana-Farber Cancer Institute), Tara Gregory(Colorado Blood Cancer Institute), Luciano J. Costa(University of Alabama at Birmingham), Jinjie Chen(Bristol-Myers Squibb (United States)), Myo Htut(City Of Hope National Medical Center), Shaoyi Li(Bristol-Myers Squibb (United States)), Kristina M. Jordahl(Bristol-Myers Squibb (United States)), Hongxiang Hu(Bristol-Myers Squibb (United States)), Lisa M. Kelly(Bristol-Myers Squibb (United States))
Cited by 1
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493